Protagonist Therapeutics, Inc. PTGX stock jumped 42.84% after the company announced topline results from its Phase 2b ...
Wave's revenue growth still lags behind expenses. Read why upside still appears to be rather long-dated for QBTS stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results